Related Experiment Videos
Diagnosis and management of primary pulmonary hypertension
1Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai.
Insights
Pediatric pulmonary hypertension (PPH) progresses rapidly, with a 2-3 year survival rate. Vasodilators and other advanced therapies offer improved outcomes for children with this condition.
Area of Science:
- Pediatric Cardiology
- Pulmonary Medicine
- Vascular Biology
Background:
- Pulmonary arterial hypertension (PAH) in children can be secondary to congenital heart defects or idiopathic (primary pulmonary hypertension - PPH).
- PPH progression is typically more rapid in children than adults, with a mean survival of 2-3 years post-diagnosis.
- Histological changes in pulmonary vasculature include medial hypertrophy, intimal hyperplasia, and plexiform lesions, leading to increased pulmonary arterial pressure and right ventricular strain.
Purpose of the Study:
- To summarize the pathophysiology, clinical presentation, and current therapeutic strategies for pediatric pulmonary hypertension.
- To highlight the rapid progression and poor prognosis of PPH in children.
- To discuss medical and interventional treatment options, including vasodilators, prostacyclin, anticoagulation, atrial septostomy, and lung transplantation.
Main Methods:
- Literature review of pediatric pulmonary hypertension.
- Analysis of histological changes in pulmonary vasculature.
- Evaluation of clinical presentation and diagnostic indicators.
- Review of current treatment modalities and their efficacy.
Main Results:
- Over 50% of children with PPH benefit from vasodilators, such as calcium channel blockers.
- Alternative treatments include inhaled nitric oxide, intravenous prostacyclin, and chronic anticoagulation.
- Interventional procedures like atrial septostomy and potential future treatments like lung transplantation are discussed.
Conclusions:
- Pediatric pulmonary hypertension is a severe condition requiring prompt diagnosis and management.
- A multi-faceted therapeutic approach, including medical, interventional, and potentially surgical options, is crucial for improving survival and quality of life.
- Further research into novel therapies, including lung transplantation, is needed for refractory cases.
Abstract:
Pulmonary arterial hypertension in children can occur secondary to shunt lesion like ventricular septal defect, patent ductus arteriosus or it may be idiopathic, the so-called primary pulmonary hypertension (PPH). The progression of PPH is usually rapid in children as compared to adults and the mean survival is 2-3 years after the diagnosis is made. Histological changes in the form of medical muscular hypertrophy, intinal hyperplasia and later angiornatous, plexiform lesions occur in pulmonary vasculature. The pulmonary vasculature normally is a high flow, low resistance circuit and allows large blood flow without marked increase in pulmonary arterial pressure. However, with prolonged increased flow or any other vasoconstrictor stimulus, histological changes start occurring in the pulmonary bed resulting in increasing pressure in pulmonary artery. Right ventricular hypertension follows resulting in right ventricular hypertrophy and later dysfunction. Life threatening arrhythmias may result in sudden death in some of these patients. Clinical presentation is in the form of exertional dyspnoea with syncope at times. Over 50% of children with PPH are helped by vasodilators. They may be treated with calcium channel blockers (e.g. nifedipine, dose titrated to blood pressure) orally. Those not responding to oral vasodilators can be put on chronic inhaled nitric oxide or continuous intravenous prostacyclin infusion. Chronic anticoagulation therapy may also increase survival. In symptomatic cases, blade/balloon atrial septostomy may increase survival in patients of PPH with intact atrial sptum. For children not responding to medical therapy, lung transplantation may be the answer in near future.